Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Insmed (Nasdaq: INSM) granted inducement awards to 92 new employees under its 2025 Inducement Plan to meet Nasdaq Listing Rule 5635(c)(4).

On November 28, 2025 the company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share (the Nasdaq closing price on the grant date).

The restricted stock units vest over four years with 25% vesting each anniversary of the first day of the month after the grant. Options have a 10-year term and a four-year vesting schedule: 25% at the first anniversary and 12.5% every six months thereafter, subject to continued service.

BRIDGEWATER, N.J., Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 92 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, on November 28, 2025, the employees received 44,273 restricted stock units and options to purchase an aggregate 2,490 shares of Insmed common stock at an exercise price of $207.77 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The restricted stock units have a four-year vesting schedule, with 25% of the shares underlying each restricted stock unit grant vesting on each anniversary of the first day of the month immediately following the grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the first day of the month immediately following the grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary thereof, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:

Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302632304.html

SOURCE Insmed Incorporated

FAQ

How many employees received inducement awards from Insmed (INSM) on November 28, 2025?

Insmed granted inducement awards to 92 new employees on November 28, 2025.

What equity did Insmed (INSM) grant under the 2025 Inducement Plan?

The company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share.

What is the vesting schedule for Insmed (INSM) restricted stock units granted as inducements?

The restricted stock units vest over four years, with 25% vesting on each anniversary of the first day of the month after the grant date, subject to continued service.

What are the terms and vesting for the inducement stock options from Insmed (INSM)?

Options have a 10-year term; vesting is 25% at the first anniversary of the first day of the month after grant and then 12.5% every six months through year four, subject to continued service.

Does Insmed (INSM) disclose the dilutive impact of the inducement grants?

The announcement lists total RSUs and option shares but does not disclose the percentage dilutive impact versus outstanding shares.

Why were the awards granted under Insmed's 2025 Inducement Plan?

The awards were made as material inducements to each employee's commencement of employment and were approved by the company's compensation committee under Nasdaq Listing Rule 5635(c)(4).